Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) unit, Xinxin Pharmaceutical Plant, was issued a drug registration certificate by the National Medical Products Administration of China, according to a Tuesday filing with the Singapore Exchange.
The certificate is for the distribution of Loxoprofen Sodium Cataplasms, which is manufactured by Beijing Baiao Pharmaceutical.
Shares of the company were up over 1% at the close of trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.